Portal de Periódicos da CAPES

Iron and chronic viral hepatitis

1997; Lippincott Williams & Wilkins; Volume: 25; Issue: 3 Linguagem: Inglês

10.1002/hep.510250345

1527-3350

Herbert L. Bonkovsky, Barbara F. Banner, Alan L. Rothman,

Viral gastroenteritis research and epidemiology

HepatologyVolume 25, Issue 3 p. 759-768 Special ArticleFree Access Iron and chronic viral hepatitis H L Bonkovsky, H L BonkovskySearch for more papers by this authorB F Banner, B F BannerSearch for more papers by this authorA L Rothman, A L RothmanSearch for more papers by this author H L Bonkovsky, H L BonkovskySearch for more papers by this authorB F Banner, B F BannerSearch for more papers by this authorA L Rothman, A L RothmanSearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1002/hep.510250345Citations: 254AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Linnen J, Wages J Jr., Zhang-Keck Z-Y, Fry KE, Krawczynski KZ, Alter H, Koonin E, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996; 271: 505–508. 2 Carreño V, Bartolome J, Castillo I. Long-term effect of interferon therapy in chronic hepatitis B. J Hepatol 1994; 20: 431–435. 3 Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Blassoni D, Colombo M. A multicenter randomized controlled trial of recombinant interferon-α2b in patients with acute trans fusion-associated hepatitis C. Hepatology 1994; 19: 19–22. 4 Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700–706. 5 Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457–1462. 6 Terrault N, Wright T. Interferon and hepatitis C. N Engl J Med 1995; 332: 1509–1511. 7 Tavill AS, Bacon BR, eds. Metals and free-radical-induced liver injury. Semin Liver Dis 1996; 16: 1–101. 8 Bullen JJ, Rogers HJ, Griffiths E. Role of iron in bacterial infection. Curr Top Microbiol Immunol 1978; 80: 1–35. 9 Bullen JJ, Ward CG, Rogers HJ. The critical role of iron in some clinical infections. Eur J Clin Microbiol Infect Dis 1991; 10: 613–617. 10 Weinberg E, Weinberg G. The role of iron in infection. Curr Opin Infect Dis 1995; 8: 164–169. 11 Caroline L, Kozinn PJ, Feldman F, Stiefel FH, Lichtman H. Infection and iron overload in thalassemia. Ann N Y Acad Sci 1969; 165: 148–155. 12 Capron JP, Carpon-Chivrac D, Tosson H. Spontaneous Yersinia enterocotitica peritonitis in idiopathic hemochromatosis. Gastroenterology 1984; 87: 1372–1374. 13 Dinarello CA. Interleukin-1. Rev Infect Dis 1984; 6: 51–95. 14 Oram JD, Reiter B. Inhibition of bacteria by lactoferrin and other ironchelating agents. Biochim Biophys Acta 1968; 170: 351–365. 15 Reiter B, Brock JH, Steel ED. Inhibition of Escherichia coli by bovine colostrum and postcolostral mil: The bacteriostatic effect of lactoferrin on a serum-susceptible and serum-resist ant strain of E. coli. Immunology 1975; 28: 83–95. 16 Lina MF, Kierszenbaum F. Lactoferrin effects on phagocytic cell function: increased uptake and killing of an intracellular parasite by murine mac-rophages and human monocytes. J Immunol 1985; 134: 4176–4183. 17 Ellison RT. The effects of lactoferrin on gram-negative bacteria. In: B Lonnerdal, TW Hutchens, SV Rumball, eds. Lactoferrin Structure and Function. New York: Plenum, 1993: 1–27. 18 Byrd TF, Horwitz MA. Lactoferrin inhibits or promotes Legionella pneumophila intracellular multiplication in nonactivated and inteferon gamma-activated human monocytes depending upon its degree of iron saturation. J Clin Invest 1991; 88: 1103–1112. 19 Kluger MJ, Bullen JJ. Clinical and physiological aspects. In: MJ Kluger, JJ Bullen, eds. Iron and Infection. Wiley, 1987: 243–282. 20 Atta M, Lamarche N, Battioni J, Massie B, Langelier Y, Mansuy D, Fontecave M. Escherichia coli and herpes-simplex-virus ribonucleotide reductase R2 subunit. Compared reactivities of the redox centers. Biochem J 1993; 290: 807–810. 21 Fujihara T, Hayashi K. Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea. Arch Virol 1995; 140: 1469–1472. 22 Hasegawa K, Motsuchi W, Tanaka S, Dosako S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn J Med Sci Biol 1994; 47: 73–85. 23 Ellison RT III, Giehl TJ. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 1991; 88: 1080–1091. 24 Harmsen MC, Swart PJ, de Bethune M, Pauwels R, De Clercq E, The TH, Meijer DKF. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995; 172: 380–388. 25 Cinatl JJ, Cinatl J, Rabenau H, Gumbel HO, Kornhuber B, Doerr HW. In vitro inhibition of human cytomegalovirus replication by desferrioxamine. Antiviral Res 1994; 25: 73–77. 26 Dai Y, Gold B, Vishwanatha JK, Rhode SL. Mimosine inhibits viral DNA synthesis through ribonucleotide reductase. Virology 1994; 205: 210–216. 27 Kawasaki Y, Isoda H, Shinmoto H, Tanimoto M, Dosako S, Idota T, Nakajima I. Inhibition by kappa-casein glycomacropeptide and lactoferrin of influenza virus hemagglutinin. Biosci Biotech Biochem 1993; 57: 1214–1215. 28 Blumberg BS, Lustbader ED, Whitford PL. Changes in serum iron levels due to infection with hepatitis B virus. Proc Natl Acad Sci USA 1981; 78: 3222–3224. 29 Lustbader ED, Harm HL, Blumberg BS. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983; 220: 423–425. 30 Ishak KG. Light microscopic morphology of viral hepatitis. Am J Clin Pathol 1976; 65: 787–827. 31 Hengeveld P, Zuyderhoudt FMJ, Jobsis AC, vanGool J. Some aspects of iron metabolism during acute viral hepatitis. Hepatogastroenterology 1982; 29: 138–141. 32 Senba M, Nakamura T, Itakura H. Statistical analysis of relationship between iron accumulation and hepatitis B surface antigen. Am J Clin Pathol 1985; 84: 340–342. 33 Sutnick AI, Blumberg BS, Lustbader ED. Elevated serum iron levels and persistent Australia antigen (HbsAg). Ann Intern Med 1974; 81: 855–856. 34 Deugnier Y, Battistelli D, Jouanolle H, Guyader D, Gueguen M, Loreal O, Jacquelinet C, et al. Hepatitis B virus infection markers in genetic haemochromatosis. A study of 272 patients. J Hepatol 1991; 13: 286–290. 35 DeVirgiliis S, Cormacchia G, Sanna G, Argiolu F, Galanello R, Fiorelli G, Rais M, et al. Chronic liver disease in transfusion-dependent thalassemia: liver iron quantitation and distribution. Acta Haematol 1981; 65: 32–39. 36 Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Laulicht M, Fenton LA, Scheuer PJ, et al. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxa-mine. J Clin Pathol 1987; 40: 1353–1359. 37 Zhou X, DeTolla L, Custer P, London WT. Iron, ferritin, hepatitis B surface and core antigens in the livers of Chinese patients with hepatocel-lular carcinoma. Cancer 1987; 59: 1430–1437. 38 Farinati RF, Cardin R, DeMaria N, Libera GD, Marafin C, Lecis E, Burra P, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449–456. 39 Barry M. Liver iron concentration, stainable iron and total body storage iron. Gut 1974; 15: 411–415. 40 Overmoyer BA, McLaren CE, Brittenham GM. Uniformity of liver density and nonheme (storage) iron distribution. Arch Pathol Lab Med 1987; 111: 549–555. 41 Villeneuve JP, Bilodeau M, Lepage R, Cole J, Lefebvre M. Variability in hepatic iron concentration measurement from needle-biopsy specimens [Abstract]. Hepatology 1994; 20: 322A. 42 Bronner MP, Kowdley KV, Carlson TH, Lin M, Labbe F. Intraorgan variability of hepatic iron concentration with hepatitis C [Abstract]. Hepatology 1995; 22: 276A. 43 Deugnier Y, Charalambous P, LeQuilleue D, Turlin B, Searle J, Brissot P, Powell LW, et al. Preneoplastic significance of hepatic iron-free-foci in genetic hemochromatosis: a study of 195 patients. Hepatology 1993; 18: 1363–1369. 44 Brittenham GM. Noninvasive methods for the early detection of hereditary hemochromatosis. Ann NY Acad Sci 1988; 526: 199–208. 45 Gandon Y, Guyader D, Heautot JF, Buhe T, Deugnier Y, Redia I-M, Yaouanq J, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 1994; 193: 533–538. 46 Rubin RB, Cable EE, Davidoff A, Stark DD, Bonkovsky HL. Improved MR method for non-invasive estimation of liver iron [Abstract]. Gastroenterology 1996; 110: A491. 47 Bonkovsky HL, Slaker DP, Bills EB, Wolf DC. Usefulness and limitations of laboratory and hepatic imaging studies in iron-storage disease. Gastroenterology 1990; 99: 1079–1091. 48 DiBisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108–2113. 49 Arber N, Konikoff FM, Moshkowitz M, Baratz M, Hallak A, Santo M, Halpern Z, et al. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 1994; 39: 2656–2659. 50 Chandra B, Hague S, Gerber MA, Lok ASI. Iron overload in chronic hepatitis C. How common is it? [Abstract]. Hepatology 1995; 22: 275A. 51 Gossard AA, Gross JR Jr., Burgant LJ, Poterucha JJ, Zein NN. Significance of iron indices in hepatitis C, alcoholic liver disease, and non-C, non-alcoholic liver diseases [Abstract]. Gastroenterology 1995; 108: A1075. 52 Zein NN, Gross JR Jr., Poterucha JJ, Gossard AA, Wendt NK, Mitchell PS, Persing DH. Significance of serum iron, iron saturation, and ferritin in patients infected with different hepatitis C genotypes [Abstract]. Gastroenterology 1995; 108: A1208. 53 Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon α therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410–415. 54 Olynyk JK, Reddy KR, DiBisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, et al. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic HCV. Gastroenterology 1995; 108: 1104–1109. 55 Izumi N, Nouchi T, Enomoto N, Tanaka Y, Uchihara M, Murakami T, Ono K, et al. Association of response to interferon with hepatic iron content in patients with hepatitis C: relationship to genotypes of HCV [Abstract]. Gastroenterology 1995; 108: A1091. Gastroenterology 1995; 103: 419–424. 58 Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol 1995; 8: 232–238. 59 Girelli CM, Mirata C, Lesingo E. Iron overload and response to alphainterferon in chronic hepatitis C. Am J Gastroenterol 1995; 90: 170. 60 Murakami CS, Wheeler D, Foster S, McIntire D, Cheng Q-C, Casey DL, Lee WM. Histology and hepatic iron content predict response to interferon in chronic hepatitis C [Abstract]. Hepatology 1995; 22: 291A. 61 Ikura Y, Morimot H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996; 91: 1367–1373. 62 Bonkovsky HL, Banner BF, Lambrecht RW, Rubin RB. Iron in liver diseases other than hemochromatosis. Semin Liver Dis 1996; 16: 65–82. 63 Fargion S, Carazzone A, Molteni V, Boldorini R, Sampietro M, Fracanzani AL, D'Alba R, et al. Iron and response to interferon alpha in chronic hepatitis C [Abstract]. Hepatology 1995; 22: 415A. 64 Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A. Hemosiderin deposition in portal endothelial cells: a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C. Hum Pathol 1995; 26: 1080–1085. 65 Bardadin KA, Scheuer PJ. Endothelial cell changes in acute hepatitis. A light and electron microscopic study. J Pathol 1984; 144: 213–220. 66 Bardadin KA, Desmet VJ. Ultrastructural observations on sinusoidal endothelial cells in chronic active hepatitis. Histopathology 1985; 9: 171–181. 67 Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986–988. 68 Bacon BR, Rebholz AE, Fried M, DiBisceglie AM. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon-α [Abstract]. Hepatology 1993; 18: 90A. 69 Van Thiel DH, Friedlander L, Malloy P, Fagiuoli S, Wright HI, Gasbarrin A, Caraceni P. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy [Abstract]. Gastroenterology 1994; 106: A1002. 70 Hayashi H, Takikawa T, Nishimura N, Yano M. Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 1995; 22: 268–271. 71 Bayraktar Y, Koseoglu T, Kayhan B, Uzunalimoglu B, Gurakar A, Van Thiel DH. The use of desferrioxamine infusion to enhance the response rate to interferon alpha treatment of chronic viral hepatitis [Abstract]. Gastroenterology 1995; 108: A1031. 72 Kugelmas M, Lieberman BY, Carey WD. Deironization in chronic hepatitis C patients previously nonresponsive to interferon improves transaminases but not viral activity [Abstract]. Gastroenterology 1995; 108: A1104. 73 Han S-H, Fong T-L, Valinluck B, Adkins RH, Redeker AG. Randomized controlled trial of the effect of iron depletion on aminotransferase levels, HCV RNA and response to interferon therapy in patients with chronic hepatitis C virus [Abstract]. Hepatology 1995; 22: 180A. 74 Yano M, Kakumu S, Takikawa T, Nishimura N. Phlebotomy followed by α-interferon therapy in patients with chronic hepatitis C [Abstract]. Hepatology 1995; 22: 119A. 75 Bacon BR, Britton RS. Hepatic injury in chronic iron overload: role of lipid peroxidation. Chem Biol Interact 1989; 70: 183–226. 76 Britton RS. Metal-induced hepatotoxicity. Semin Liver Dis 1996; 16: 3–12. 77 Higueras V, Raya A, Rodrigo JM, Serra MA, Roma J, Romer FJ. Interferon decreases serum lipid peroxidation products of hepatitis C patients. Free Radic Biol Med 1994; 16: 131–133. 78 Kikuyama M, Kobayashi Y, Kawasaki T, Yoshimi T. Hepatic lipid peroxidation in chronic hepatitis C [Abstract]. Hepatology 1995; 24: 275A. 79 Giostra E, Male PJ. Traitement de l'hepatite virale C: quelles perspectives? Revue Medicale de la Suisse Romande 1994; 114 (supp): 759–764. 80 Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29–60. 81 Gonzalez-Peralta RP, Davis GL, Lau JYN. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 1994; 21: 255–259. 82 Mondelli MU, Cerino A, Bellotti V, deKoning A. Immunobiology and pathogenesis of hepatitis C virus infection. Res Virol 1993; 144: 269–274. 83 Cerny A, Chisari FV. Immunological aspects of HCV infection. Intervirology 1994; 37: 119–125. 84 Sherman KE, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, Wilber J. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993; 31: 2679–2682. 85 Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 1994; 18: 339–347. 86 Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41–63. 87 Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, Houghton M, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A 1995; 92: 2755–2759. 88 Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Sette A, Penna A, et al. Cytotoxic T lymphocyte responses to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994; 180: 933–943. 89 van Doorn L, Capriles I, Maertens G, DeLeys R, Murray K, Kos T, Schellekens H, et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol 1995; 69: 773–778. 90 Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, de Carli M, Fiaccadori F, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994; 369: 407–410. 91 Cerny A, Ferrari C, Chisari FV. The class I-restricted cytotoxic T lymphocyte response to predetermined epitopes in the hepatitis B and C viruses. Curr Top Microbiol Immunol 1994; 189: 169–186. 92 Doherty PC. Immune exhaustion: driving virus-specific CD8+ T cells to death. Trends Microbiol 1993; 1: 207–209. 93 Sher A, Gazzinelli RT, Oswald IP, Clerici M, Kullberg M, Pearce EJ, Berzofsky JA, et al. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev 1992; 127: 183–204. 94 Actor JK, Shirai M, Kullberg MC, Buller RM, Sher A, Berzofsky JA. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Thl cytokine responses as well as delayed virus clearance. Proc Natl Acad Sci U S A 1993; 90: 948–952. 95 Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 227–257. 96 Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138–146. 97 Breedveld FC, Dynesius-Trentham R, de Sousa M, Trentham DE. Collagen arthritis in the rat is initiated by CD4+ T cells and can be amplified by iron. Cellular Immunol 1989; 121: 1–12. 98 Blake DR, Lunec J, Ahern M, Ring EFJ, Bradfield J, Gutteridge JMC. Effect of intravenous iron dextran on rheumatoid synovitis. Ann Rheum Dis 1985; 44: 182–188. 99 Good MF, Powell LW, Halliday JW. The effect of non-transferrin-bound iron on murine T lymphocyte subsets: analysis by clonal techniques. Clin Exp Immunol 1987; 70: 164–172. 100 Rudd MJ, Good MF, Chapman DE, Powell LW, Halliday JW. Clonal analysis of the effect of iron on human cytotoxic and proliferating T lymphocytes. Immunol Cell Biol 1990; 68: 317–324. 101 Seligman PA, Kovar J, Gelfand EW. Lymphocyte proliferation is controlled by both iron availability and regulation of iron uptake pathways. Pathobiology 1992; 60: 19–26. 102 Thibault H, Galan P, Selz F, Preziosi P, Olivier C, Badoual J, Hercberg S. The immune response in iron-deficient young children: effect of iron supplementation on cell-mediated immunity. Eur J Pediatr 1993; 152: 120–124. 103 Omara OF, Blakley BR. The effects of iron deficiency and iron overload on cell-mediated immunity in the mouse. Br J Nutr 1994; 72: 899–909. 104 Andrews FJ, Morris CJ, Kondratowicz G, Blake DR. Effect of iron chelation on inflammatory joint disease. Ann Rheum Dis 1987; 46: 327–333. 105 Bowern N, Ramshaw IA, Clark IA, Doherty PC. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J Exp Med 1984; 160: 1532–1543. 106 Mendola J, Wright JRJ, Lacy PE. Oxygen free-radical scavengers and immune destruction of murine islets in allograft rejection and multiple low-dose streptozocin-induced insulitis. Diabetes 1989; 38: 379–385. 107 Whitley WD, Hancock WW, Kupiec-Weglinsky JW, de Sousa M, Tilney NL. Iron chelation suppresses mononuclear cell activation, modifies lymphocyte migration patterns, and prolongs rat cardiac allograft survival in rats. Transplantation 1993; 56: 1182–1188. 108 Thorson JA, Smith KM, Gomez F, Naumann PW, Kemp JD. Role of iron in T cell activation: TH1 clones differ from TH2 clones in their sensitivity to inhibition of DNA synthesis caused by IGG Mabs against the transferrin receptor and the iron chelator deferoxamine. Cell Immunol 1991; 134: 126–137. 109 Tsukamoto H, Home W, Kamimurä S, Niemela O, Parkkila S, Yiä-Hert-tuala S, Brittenham GM. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 1995; 96: 620–630. 110 Boucher E, Bourienne A, Turlin B, Moirand R, Brissot P, Deugnier Y. Reduction of liver iron content following treatment of chronic hepatitis C [Abstract]. Hepatology 1995; 22: 397A. 111 Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi M, et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051–1055. 112 Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141–147. 113 DiBisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994; 21: 1109–1112. 114 Fiel MI, Guido M, Thung SN, Lindsay KL, Davis GL, Lewis IH, Seeff L, et al. Hepatic iron deposition during ribavirin therapy of chronic hepatitis C [Abstract]. Hepatology 1995; 22: 290A. 115 Rakela J, Redeker AG, Weliky B. Effect of short-term prednisone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis. Gastroenterology 1983; 84: 956–960. 116 Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81: 987–991. 117 Fong T, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196–199. 118 Magrin S, Craxi A, Fabiano C, Simonetti RG, Florentine G, Marino L, Diquattro O, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-α or corticosteroid treatment. Hepatology 1994; 19: 273–279. Citing Literature Volume25, Issue3March 1997Pages 759-768 ReferencesRelatedInformation